Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free.
An advisory panel to the U.S. Food and Drug Administration on Tuesday endorsed Pfizer’s COVID vaccine for children ages 5 to 11, despite strong objections raised during the meeting by multiple scientists and physicians.
The FDA invited Steve Kirsch, founder of the COVID-19 Early Treatment Fund, to give a presentation during the open session of the Related Biological Products Advisory Committee meeting.
Kirsch prepared 100 questions for the committee and 161 slides, but his allotted time — three minutes — meant he had to shorten the presentation to just 30 slides. However, he has made the full set of slides available to the public.
Among the questions Kirsch asked was this: How could committee members do a risk-benefit analysis with Pfizer’s COVID vaccine if they did not know the under-reporting factor (URF) of the Vaccine Adverse Event Reporting System (VAERS)?
“This is extremely, extremely important,” Kirsch told the committee. “You have been assuming it has been one. It is not one. Using a URF of 41, which is calculated using CDC [Centers for Disease Control and Prevention] methodology, we find more than 300,000 excess deaths in VAERS. If the vaccine didn’t kill these people, what did?”
Kirsch added: “How many Americans have to die before you pull the plug?”
Kirsch also questioned the panel on why Maddie de Garay’s severe adverse reaction to the Pfizer vaccine, which left her paralyzed, was not reported by the company to the FDA.
“There are 28 million kids 5 to 11,” Kirsch pointed out in one of his slides. “Shouldn’t we be super careful here? How many deaths will we prevent? How can you be absolutely sure deaths from vaccines aren’t > deaths from COVID like all the data says?”
Kirsch said he believes all of the questions he asked needed to be fully answered before any vote to authorize vaccination for 5- to 11-year-olds.
“After all, once you’ve been vaccinated, you can never be unvaccinated,” he said.
View Kirsch’s entire presentation here.